Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05181995 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy of 50 mg NYX-783 QD vs. Placebo in PTSD
A Phase 2 study, sponsored by Aptinyx.
- Terminated
- Registry status
- Phase 2
- Development phase
- 121
- Enrollment target
NCT05181995 is a Phase 2 study that was terminated before completion, run by Aptinyx. The registered enrollment target is 121 participants.
The verdict
NCT05181995, a Phase 2 study, was terminated before completion, sponsored by Aptinyx.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 121 participants
- Enrollment target
Study Summary
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of 50 mg NYX-783 Once Daily Compared to Placebo in Participants with Post-Traumatic Stress Disorder (PTSD)
Interventions
- DRUG Placebo
- DRUG NYX-783
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 121 participants |
| Start Date | 2021-12-13 |
| Est. Completion | 2023-03-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05181995
The ClinicalTrials.gov registry entry for NCT05181995 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 121 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Aptinyx, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05181995 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05181995 about?
NCT05181995 is a clinical study titled "Safety and Efficacy of 50 mg NYX-783 QD vs. Placebo in PTSD". A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of 50 mg NYX-783 Once Daily Compared to Placebo in Participants with Post-Traumatic Stress Disorder (PTSD)
What is the current status of trial NCT05181995?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 121 participants. The study started on 2021-12-13. Estimated completion is 2023-03-30.
What interventions are being tested in trial NCT05181995?
The interventions under investigation include: Placebo (DRUG), NYX-783 (DRUG).
Who is sponsoring clinical trial NCT05181995?
This trial is sponsored by Aptinyx, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.